- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
AZ and Lilly Extend Immuno-oncology Collaboration
October 23, 2015.
Eli Lilly and Company and AstraZeneca (AZ) have announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.
Lilly and AZ will evaluate the safety and efficacy of a range of additional combinations across the companies' complementary portfolios. Lilly will lead the execution of the studies, while both companies will contribute resources.
AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), will be combined with Lilly molecules that target the immune system. The companies will also explore other combinations targeting tumor drivers and resistance mechanisms, it is reported.
Earlier this year, Lilly and AstraZeneca announced a Phase I clinical trial collaboration to evaluate the safety and preliminary efficacy of combining durvalumab and ramucirumab as a treatment for patients with advanced solid tumors.
